JP2021524844A5 - - Google Patents
Info
- Publication number
- JP2021524844A5 JP2021524844A5 JP2020564095A JP2020564095A JP2021524844A5 JP 2021524844 A5 JP2021524844 A5 JP 2021524844A5 JP 2020564095 A JP2020564095 A JP 2020564095A JP 2020564095 A JP2020564095 A JP 2020564095A JP 2021524844 A5 JP2021524844 A5 JP 2021524844A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- human
- alkylthioalkyl
- thioalkyl
- Prior art date
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024003447A JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2025142520A JP2026000929A (ja) | 2018-05-15 | 2025-08-28 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671964P | 2018-05-15 | 2018-05-15 | |
| US62/671,964 | 2018-05-15 | ||
| PCT/US2019/032461 WO2019222380A1 (en) | 2018-05-15 | 2019-05-15 | Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003447A Division JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021524844A JP2021524844A (ja) | 2021-09-16 |
| JP2021524844A5 true JP2021524844A5 (https=) | 2022-05-23 |
| JPWO2019222380A5 JPWO2019222380A5 (https=) | 2022-05-23 |
| JP7421499B2 JP7421499B2 (ja) | 2024-01-24 |
Family
ID=66691010
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564095A Active JP7421499B2 (ja) | 2018-05-15 | 2019-05-15 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2024003447A Active JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2025142520A Pending JP2026000929A (ja) | 2018-05-15 | 2025-08-28 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003447A Active JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2025142520A Pending JP2026000929A (ja) | 2018-05-15 | 2025-08-28 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210186972A1 (https=) |
| EP (2) | EP4721727A2 (https=) |
| JP (3) | JP7421499B2 (https=) |
| AU (2) | AU2019271208B2 (https=) |
| CA (1) | CA3100211A1 (https=) |
| ES (1) | ES3061722T3 (https=) |
| WO (1) | WO2019222380A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| JP2020514252A (ja) | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
| CA3092677A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| CN118908962A (zh) | 2019-05-06 | 2024-11-08 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| WO2022159650A1 (en) * | 2021-01-22 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2 |
| US20260028342A1 (en) * | 2022-07-29 | 2026-01-29 | The University Of North Carolina At Chapel Hill | Enhancing antimetastasis activity using targeted protein degradation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| CA2719803A1 (en) * | 2008-03-28 | 2009-10-01 | University Of Massachusetts | Compositions and methods for the preparation of nanoemulsions |
| TR201905480T4 (tr) * | 2008-04-18 | 2019-05-21 | Angiochem Inc | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. |
| EP2791142B1 (en) * | 2011-12-16 | 2019-07-03 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
| US9877966B1 (en) * | 2015-08-10 | 2018-01-30 | Eugene J. Oliva | Combination therapy for the inhibition of metastasis and tumorigenesis |
| TWI838700B (zh) * | 2015-09-30 | 2024-04-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| US11241436B2 (en) * | 2017-01-25 | 2022-02-08 | Northwestern University | Autophagy inducers for treatment of CNS conditions |
-
2019
- 2019-05-15 JP JP2020564095A patent/JP7421499B2/ja active Active
- 2019-05-15 AU AU2019271208A patent/AU2019271208B2/en active Active
- 2019-05-15 ES ES19728226T patent/ES3061722T3/es active Active
- 2019-05-15 CA CA3100211A patent/CA3100211A1/en active Pending
- 2019-05-15 EP EP25214810.1A patent/EP4721727A2/en active Pending
- 2019-05-15 US US17/055,256 patent/US20210186972A1/en not_active Abandoned
- 2019-05-15 WO PCT/US2019/032461 patent/WO2019222380A1/en not_active Ceased
- 2019-05-15 EP EP19728226.2A patent/EP3793523B8/en active Active
-
2024
- 2024-01-12 JP JP2024003447A patent/JP7736825B2/ja active Active
- 2024-06-06 US US18/735,506 patent/US20240316056A1/en active Pending
-
2025
- 2025-05-12 AU AU2025203402A patent/AU2025203402A1/en active Pending
- 2025-08-28 JP JP2025142520A patent/JP2026000929A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524844A5 (https=) | ||
| JP7492002B2 (ja) | Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法 | |
| ES2312568T3 (es) | Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo. | |
| ES2279407T3 (es) | Combinaciones antineoplasicas. | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| WO2016161361A4 (en) | Compositions and methods of targeting mutant k-ras | |
| WO2010086964A1 (ja) | がん治療のための併用療法 | |
| US8349792B2 (en) | Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent | |
| AU2007264665A1 (en) | Potentiator of radiation therapy | |
| JPWO2019169065A5 (https=) | ||
| US10220072B2 (en) | Mesalamine for the treatment of cancer | |
| JPWO2019222380A5 (https=) | ||
| EP2754441A2 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | |
| Chu et al. | Basic and clinical pharmacology | |
| CA2993127A1 (en) | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer | |
| JPWO1992004028A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| US8124593B2 (en) | Methods of treatment using sapacitabine | |
| JP2020176071A (ja) | 血液がんの新規治療法及び新規治療剤 | |
| WO1999012542A1 (en) | 8a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS | |
| JPWO2022246459A5 (https=) | ||
| US11179349B2 (en) | Use of tumor gene methylation regulator and anti-tumor drugs | |
| US10098860B2 (en) | Bezafibrate for the treatment of cancer | |
| CN113631166A (zh) | 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合 | |
| WO2017080313A1 (en) | Tetrahydropalmatine derivative, its preparation method and use | |
| JP2014034531A (ja) | Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ |